Предикторы эффективности иммуносупрессорной терапии при тяжелой коронавирусной инфекции

Андреев А.А.

Figure 1. The course of COVID-19 and General Approach to treatment



EVMS COVID-19 MANAGEMENT PROTOCOL

An overview of the MATH+ and I-MASK+ Protocols

Developed and Updated by Paul Marik, MD, FCP (SA), FRCP (C), FCCP, FCCM.
Professor of Medicine, Chief of Pulmonary and Critical Care Medicine
Eastern Virginia Medical School
December 12th, 2020

Figure 2. Timing of the initiation of anti-inflammatory therapy



EVMS COVID-19 MANAGEMENT PROTOCOL

An overview of the MATH+ and I-MASK+ Protocols

Developed and Updated by Paul Marik, MD, FCP (SA), FRCP (C), FCCP, FCCM.
Professor of Medicine, Chief of Pulmonary and Critical Care Medicine
Eastern Virginia Medical School
December 12th, 2020



The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Cytokine Storm

David C. Fajgenbaum, M.D., and Carl H. June, M.D.

MEDACH

15 October 1993 Volume 119 Number 8

Annals of Internal Medicine

Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome

Larry C. Casey, MD, PhD; Robert A. Balk, MD; and Roger C. Bone, MD

При сепсисе повышение уровня цитокинов ИЛ-1β, ИЛ-6, ФНОα в крови более показательно и прямо коррелирует со смертностью в сравнении с уровем бактериального ЛПС.

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

Kevin J. Tracey*‡, Yuman Fong*, David G. Hesse*, Kirk R. Manogue‡, Annette T. Lee‡, George C. Kuo†, Stephen F. Lowry*§ & Anthony Cerami‡

Nature, 1987

Введение антител к ФНОα за 2 часа до введения летальной дозы E. Coli профилактировало у лабораторных животных развитие септического шока, СПОН и летального исхода.